Emergence of *TP53* mutation during lenalidomide therapy of myelodysplastic syndrome with del(5q) and its subsequent disappearance following salvage therapy with decitabine

According to the International Consensus Classification (ICC), diagnosis of myelodysplastic syndrome (MDS) with del(5g) requires presence of i) del5g, alone or associated with no more than one other cytogenetic abnormality, exclusive of -7/del(7q), ii) <5% bone marrow (BM) and <2% circulating blasts, and iii) the absence of "multi-hit" TP53.¹ The latter is defined by the ICC as the presence of i) two or more distinct TP53 mutations, each with variant allele frequency (VAF) \geq 10%, ii) a single *TP53* mutation with VAF \geq 50%, or iii) a single *TP53* mutation with VAF \geq 10% accompanied by a cytogenetically-apparent del(17p13.1), copy-neutral loss of heterozygosity (LOH) at the TP53 locus, or, in the absence of loss of heterozygosity (LOH) information, complex karyotype.¹ MDS-del(5g) is uniquely characterized by its relatively indolent clinical course and its sensitivity to treatment with lenalidomide.²⁻⁴

Patients with MDS-del(5g) are known to harbor multiple somatic mutations with the two most frequent ones being TP53 (~20% incidence at diagnosis) and SF3B1 (~18%).⁵ These two mutations display significant clustering and are more prevalent in leukemic phase disease, with an estimated 50% incidence.⁵ The latter suggests vulnerability or pathogenetic contribution to progression into acute myeloid leukemia (AML). In this regard, we have recently reported on TP53 VAF >22% as being the most prominent risk factor for leukemic progression and overall survival in MDS-del(5q).⁵ These observations were consistent with an earlier report suggesting adverse impact of strong P53 protein expression on cytogenetic response and overall and leukemia-free survival in MDS-del(5g).⁶ Consistent with these observations, a 2018 report in Haematologica described the emergence of TP53 mutations and disease progression during lenalidomide therapy, in patients with MDS-del(5q).⁷ In the current case report of a patient with MDS-del(5g), we confirm the acquisition of TP53 mutation during lenalidomide therapy and, in addition, we describe, for the first time, successful salvage therapy with 3-day decitabine, resulting in resolution of transfusion need, cytogenetic remission, and elimination of mutant TP53 and SF3B1 clones. Informed consent was obtained from the patient.

Our patient was first diagnosed with MDS-del(5q) at 75 years of age in May 2021. Co-morbidities included history of hemochromatosis (diagnosed in 2008 based on serum ferritin value of 1,553 mcg/L and liver biopsy that showed

moderate hemosiderosis but with no documentation of genotyping and subsequently treated with phlebotomy in the remote past), atrial fibrillation, non-ischemic cardiomyopathy, mitral regurgitation, and alcohol use. The earliest complete blood count (CBC) record from January 2012 showed hemoglobin 14.1 g/dL, mean corpuscular volume (MCV) 97.3 FL, platelet count 277x10⁹/L and leukocyte count 6.3x10⁹/L. Macrocytosis without anemia first appeared in July 2013 (MCV 103.7 FL) and by July 2015, MCV was 107.7 FL and hemoglobin 12.9 g/dL. Subsequently, his anemia worsened progressively until he required two units of packed red cell transfusion 10 days prior to his first visit to our institution in May 2021. At that time, physical examination did not reveal palpable spleen, liver, or lymph nodes; CBC showed hemoglobin 8.9 g/dL, MCV 130.9 FL, leukocyte count 4.2x10⁹/L, absolute neutrophil count (ANC) 1.96x10⁹/L, platelet count 152x10⁹/L, normal serum B12 and folate, serum ferritin 172 mcg/dL, serum erythropoietin level 225 mIU/mL, and no circulating blasts. Bone marrow (BM) examination revealed normocellular marrow with 1% blasts and dysmegakaryopoiesis (monolobated and bilobate forms). Cytogenetic studies revealed isolated 5g deletion in eight (40%) of 20 metaphases (46,XY,del(5) (q13q33)[8]/46,XY[12]). Next-generation sequencing (NGS) of BM samples revealed DNMT3A (VAF 23%) and SF3B1 (VAF 14%) mutations, only (Figures 1 and 2).

Treatment with lenalidomide (10 mg daily) was initiated on June 16, 2021, and the patient became transfusion-independent within 3 months of treatment. Lenalidomide dose was reduced to 7.5 mg/day on May 13, 2022 because of treatment-emergent diarrhea that did not get better and was subsequently attributed to another cause, leading to treatment resumption at 10 mg/day dose (patient remained transfusion-independent during this period). CBC from January 2022 showed hemoglobin 12.8 g/dL, MCV 112.1 FL, leukocyte count 5.2x10⁹/L and platelet count 264x10⁹/L. By December 2022, the patient had relapsed with transfusion-dependent anemia: hemoglobin 6.0 g/dL, MCV 124.7 FL, leukocyte count 3.2x10⁹/L, ANC 0.83x10⁹/L, and platelet count 53x10⁹/L. BM examination at the time showed normocellular marrow with slightly increased blasts (5%), and persistent dysmegakaryopoiesis (Figures 1 and 2). Cytogenetic studies revealed isolated 5q deletion in 13 (65%) of 20 metaphases (46,XY,del(5)(q13q33) [13]/46,XY[7]). BM NGS revealed clonal expansion of DN-

Bone marrow Normocellular Dysplastic (del 5q) megakaryo No other dysplasia Blasts 1%	Bone marrow Normocellular Dysplastic (del 5q) megakaryocytes No other dysplasia Blasts 5% Cytogenetics Isolated del(5q)	Bone marrow Hypocellular Dysplastic (del 5q) megakaryocytes persist No other dysplasia Blasts <1%
Cytogenetics	13/20 metaphases	Cytogenetics Isolated del(5q)
Isolated del(5q) 8/20 metaphases	Mutations identified	1/20 metaphases
Mutations identified SF3B1 14% VAF DNMT3A 23% Transfusion-dependent Lenalidomide 10 mg/daily Days 1-21 monthly Transfusion-	SF3B1 32% VAF DNMT3A 36% TP53 31% RUNX1 2% Transfusion-dependent Initiation of Decitabine 20 mg/m ² days 1-3 Held (1/9/23) No response No response	MutationsidentifiedSF3B1 not detectedDNMT3A 8%TP53 not detectedRUNX1 2%Transfusion-independent5th cycle4 cycles(10/18/23)Transfusion-
dependent	Transfusion- independent Transfusion- independent dependent	Independent Independent after cycle 2
Diagnosis (5/24/2021)	Relapse (12/15/2022) Transfusion- dependent	Follow-up bone marrow biopsy (10/3/2023)

Figure 1. Timeline of disease course and treatment history of a 75-year-old man with myelodysplastic syndromes with del(5q). VAF: variant allele frequency; HgB: hemoglobin B.

MT3A (VAF 36%) and SF3B1 (VAF 32%) mutations, as well as emergence of two new mutations: TP53 (VAF 31%), and RUNX1 (VAF 2%). Lenalidomide was held on January 9, 2023 and resumed on January 19, 2023 without any benefit and treatment discontinued on April 26, 2023. Salvage therapy with lower-dose decitabine (20 mg/m² daily x 3 days, per 28-day cycle) was initiated on May 24, 2023, and the patient became transfusion-independent after the second cycle of treatment and has remained transfusion-independent to date (October 18, 2023); the 3-day versus the standard 5-day dose schedule for decitabine was chosen based on patient fraility. A follow-up BM examination performed on March 10, 2023, showed hypocellular marrow with <1% blasts and persistence of small hypolobated megakaryocytes, although decreased in number; cytogenetic studies revealed isolated 5q deletion in only one of (5%) of 20 metaphases (46,XY,del(5) (q13q33)[1]/46,XY[19]). BM NGS revealed disappearance of both the TP53 and SF3B1 mutant clones and a decrease in mutant allele burden for DNMT3A (VAF 8%) while RUNX1 (VAF 2%) remained unchanged (Figures 1 and 2). The current case report confirms observations from recent

reports that suggest the emergence or clonal expansion of TP53 mutations during treatment with lenalidomide.^{7,8} In a cohort of 24 patients with MDS-del(5g), 18 (75%) had an erythroid response during lenalidomide therapy and five (21%) a complete cytogenetic response;⁷ a *TP53* mutation was detected in six (25%) patients at diagnosis and in an additional nine (38%) patients during follow-up, of whom, one also manifested a new RUNX1 mutation, as was the case in the current report (median duration of exposure to lenalidomide was 11 months).⁷ The particular study also showed a correlation between TP53 clonal evolution and disease progression.⁷ In another report of 416 patients with therapy-related myeloid neoplasms, the authors described an association between TP53 mutations and prior treatment with thalidomide analogs, specifically lenalidomide.⁸ In the latter report, the authors were able to provide experimental evidence for lenalidomide-induced selective advantage for TP53 mutant clones.² What is novel in our case report was the successful treatment with 3-day (instead of the standard 5-day) decitabine, culminating not only in resolution of transfusion-need but also in inducing major cytogenetic and molecular re-




Figure 2. Sequential bone marrow examination. A 75-year-old man with myelodysplastic syndromes with del(5q) diagnosed on May 24, 2021 was treated initially with lenalidomide but lost response by December 15, 2022 and was successfully salvaged with decitabine therapy on March 10, 2023. VAF: variant allele frequency.

mission, including the eradication of the *TP53* mutation; it is difficult, based on a single case report, to comment on whether or not the 3-day, as opposed to the standard 5-day, decitabine dosing schedule made a difference or whether we would have been as successful using azacytidine instead of decitabine.

There are a number of practically important suggestions that can be extrapolated from the current case report, but only after confirmation from additional studies. At the minimum, it is reasonable to recommend NGS in all patients with MDS-del(5q) at diagnosis as well as periodically during treatment with lenalidomide. In the event of treatment-emergent TP53 mutations or clonal expansion, we would recommend addition or switching to hypomethylating agents and continue monitoring TP53 VAF. The particular treatment strategy is also relevant in the context of bridging chemotherapy, in preparation for allogeneic stem cell transplant, which is currently the only treatment modality that can secure long-term survival in MDS-del(5g)⁹ as well as *TP53*-mutated myeloid neoplasms, especially if not associated with complex karyotype,¹⁰ which would be the case in MDS-del(5q); whether or not treatment success can further be enhanced with the

addition of venetoclax to hypomethylating agent therapy is plausible but needs to be studied.

Authors

Naseema Gangat,¹ Naresh Bellam,² Kaaren Reichard¹ and Ayalew Tefferi¹

¹Mayo Clinic, Rochester, MN and ²Montgomery Cancer Center, Prattville Campus, Prattville, AL, USA

Correspondence:

N. GANGAT - gangat.naseema@mayo.edu

A. TEFFERI - tefferi.ayalew@mayo.edu

https://doi.org/10.3324/haematol.2023.284547

Received: October 25, 2023. Accepted: November 20, 2023. Early view: November 30, 2023.

©2024 Ferrata Storti Foundation Published under a CC BY-NC license 🖭 👀



Disclosures

No conflicts of interest to disclose.

Contributions

NG and AT co-wrote the paper. NB participated in patient care. KR

reviewed bone marrow morphology and genetic studies. All authors reviewed and approved the final draft of the paper.

Data-sharing statement

Please email the corresponding author to obtain original data.

References

- 1. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200-1228.
- 2. Patnaik MM, Lasho TL, Finke CM, et al. WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia. 2010;24(7):1283-1289.
- List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352(6):549-557.
- Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusiondependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118(14):3765-3776.
- 5. Fleti F, Chan O, Singh A, et al. TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): a Mayo-Moffitt study of 156 informative cases. Am J Hematol.

2023;98(4):E76-E79.

- Saft L, Karimi M, Ghaderi M, et al. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica. 2014;99(6):1041-1049.
- Lode L, Menard A, Flet L, et al. Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide. Haematologica. 2018;103(4):e143-e146.
- 8. Sperling AS, Guerra VA, Kennedy JA, et al. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood. 2022;140(16):1753-1763.
- 9. Garderet L, Ziagkos D, van Biezen A, et al. Allogeneic stem cell transplantation for myelodysplastic syndrome patients with a 5q deletion. Biol Blood Marrow Transplant. 2018;24(3):507-513.
- Pasca S, Haldar SD, Ambinder A, et al. Outcome heterogeneity of TP53-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation. Haematologica. 2023 Sep 21. doi: 10.3324/haematol.2023.283886. [Epub ahead of print].